Analysts expect Aflac Incorporated to report Q2 2026 revenue of $4.19 billion and an EPS of $1.77, while the current stock price of $126.71 trades well above the average analyst price target of $117.71.
Investors are predominantly focused on the operational recovery and sales momentum in the Aflac Japan segment following a late-June 2026 cybersecurity breach that exposed policyholder data.
Despite a slight Q1 earnings miss due to elevated benefit ratios, Japan's new sales recently surged 25.5% behind the success of the Anshin Palette medical product.
Management’s commentary on sustaining its 43-year dividend growth streak and $1 billion share buyback plan remains a critical pillar for shareholder confidence at current valuation levels.